(NASDAQ: ABVX) Abivax Sa's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Abivax Sa's revenue in 2025 is N/A.On average, 3 Wall Street analysts forecast ABVX's revenue for 2025 to be $553,201,748, with the lowest ABVX revenue forecast at $372,902,244, and the highest ABVX revenue forecast at $901,814,611. On average, 2 Wall Street analysts forecast ABVX's revenue for 2026 to be $535,888,429, with the lowest ABVX revenue forecast at $372,902,244, and the highest ABVX revenue forecast at $698,874,614.
In 2027, ABVX is forecast to generate $7,641,515,323 in revenue, with the lowest revenue forecast at $5,715,931,847 and the highest revenue forecast at $9,673,895,972.